Arecor Ltd United Kingdom

Arecor has a proprietary and patented technology platform for improving the stability of a range of therapeutic proteins including vaccines, monoclonal antibodies, peptides, blood factors and fusion proteins

Organisation Type
Dr Sarah Howell
Chief Operations Officer & Communications Strategy Group United States

The Communications Strategy Group Inc. is US-based consultancy providing corporate/financial communications and business development services to the life sciences, biotech and medical technology sectors; assist and advise UK and EU companies seeking to expand to the US; corporate mentoring; assets partnering; capital formation.

The Communications Strategy Group Inc. acts as a contact point for UK companies attending US conferences, in partnership with, a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK. BioPartner is a membership organisation, supporting UK SMEs and startups, and signposting organisations worldwide to UK expertise. has alliances with organisers of international biopartnering events, and with UK membership organisations, operating both independently and in partnership with the UK government. BioPartner disseminates tradeshow access grants to help UK-based SMEs exhibit their services and products in new overseas markets.

Organisation Type
Mr Ted Agne
LinkedIn logo President 
Ms Lin Bateson
(not attending) 

Domainex United Kingdom

Domainex is a drug discovery company with a reputation for speed and innovation built on an exceptional track record of drug candidate delivery. It has a world class discovery team with an unrivalled track record and three client drug candidates

Organisation Type
Dr Eddy Littler
Chief Executive Officer 
Dr Keith Powell

Haemostatix United Kingdom

Haemostatix has developed a new class of peptide-based haemostat for the treatment of bleeding. The technology is based on a peptide that binds to the blood protein fibrinogen, inducing the rapid and targeted formation of clots.

Organisation Type
Dr Ben Nichols
Chief Executive Officer 

Integrated Magnetic Systems Ltd United Kingdom

IMS offers magnetic antibodies and adaptor proteins to the life science community (research and bioprocessing) while further developing the technology platform for licensing and partnering opportunities in medicine (diagnostics and therapeutics).

Organisation Type
Dr Eddie Blair
Chief Executive Officer 

International Bioscience Managers United Kingdom

IBML, through its associate companies, OctaPhillip Bioscience Managers Ltd and Union MedTech PLC, specialises in investment in life science and medical technology companies.

Organisation Type
Mr Jeremy Curnock Cook
Managing Director 

Kymab United Kingdom

Kymab is a biopharmaceutical company engaged in the discovery and development of human monoclonal antibody therapeutics.

Organisation Type
Dr Tom Shepherd
Chief Business Officer 

PolyTherics Ltd United Kingdom

PolyTherics is a biotechnology company that offers a comprehensive range of site-specific conjugation technologies and polymer-based technologies which are being applied to the development and enhancement of biologicals and other therapeutic entities.

Organisation Type
Dr John Burt
Chief Executive Officer 
Dr Jennifer Filbey
US consultant 

Prosonix Ltd United Kingdom

Prosonix is a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines enabled by its state-of-the-art particle engineering technology.

Organisation Type
Mr David Hipkiss
Chief Executive Officer 
Mr Andy Bush
Chief Operating Officer 

Reneuron United Kingdom

ReNeuron is a leading, clinical-stage stem cell business. Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

Organisation Type
Dr John Sinden
Chief Scientific Officer